serous carcinoma

serous carcinoma is …
instance of (P31):
diseaseQ12136

sublass of (P279):
carcinomaQ33525
Serous tumourQ7455063

External links are
P2892UMLS CUIC0476127

Reverse relations

subclass of (P279)
Q28134897high-grade serous carcinoma
Q123750979low-grade serous carcinoma
Q18553575ovarian serous carcinoma
Q7455060serous cystadenocarcinoma

main subject (P921)
Q44049813"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer
Q940952292317 Uterine serous carcinoma is associated with a high risk of venous thromboembolism regardless of latency from surgical staging
Q90939662A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
Q89752152A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy
Q30489669A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma
Q92336127A Comprehensive Review of Ovarian Serous Carcinoma
Q108589263A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
Q91470904A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
Q98501449A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles from Culture Supernatant of Human Ovarian Cancer Cell Line A2780 and Body Fluids of High-Grade Serous Carcinoma Patients
Q85112334A Unique case of primary squamous carcinoma of the salpinx associated with serous carcinoma of the omentum: a pathological and molecular study
Q35980522A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006
Q33264156A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Q42045828A case of minimal uterine serous carcinoma with distant lymph node metastasis without peritoneal dissemination
Q67387730A case of ovarian papillary serous carcinoma of low malignant potential
Q37651338A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?
Q48344395A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Q36138088A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer
Q34111959A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Q28295789A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary
Q40205750A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model
Q92041750A novel model to predict cancer-specific survival in patients with early-stage uterine papillary serous carcinoma (UPSC)
Q33347156A pilot study of topotecan in the treatment of serous carcinoma of the uterus
Q36737086A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium.
Q89568510A retrospective study for investigating the relationship between old and new staging systems with prognosis in ovarian cancer using gynecologic cancer registry of Japan Society of Obstetrics and Gynecology (JSOG): disparity between serous carcinoma
Q36520687A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome
Q92609149A successfully treated primary peritoneal carcinosarcoma and serous carcinoma of stage IIIC rescued from hypovolemic shock due to tumor rupture
Q34387999A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
Q82293644A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases
Q92416619ADNP (Activity Dependent Neuroprotector Homeobox): A novel oncogene driving poor prognosis in high-grade serous carcinoma
Q88072881APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Q85655227AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
Q41970635Abdominal wall metastasis of uterine papillary serous carcinoma in a post-menopausal woman: a case report
Q83986440Abnormal cervical cytology in the diagnosis of uterine papillary serous carcinoma: earlier detection of a poor prognostic cancer subtype?
Q90387906Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
Q58080932Adjuvant Pelvic Radiation "Sandwiched" Between Paclitaxel/Carboplatin Chemotherapy in Women With Completely Resected Uterine Serous Carcinoma: Long-term Follow-up of a Prospective Phase 2 Trial
Q81574394Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma
Q97517002Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium
Q67974898Adjuvant whole-abdominal radiation therapy in uterine papillary serous carcinoma
Q50225470Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come
Q35887356Advanced papillary serous carcinoma of the uterine cervix: a case with a remarkable response to paclitaxel and carboplatin combination chemotherapy
Q37676705Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis
Q36696435Alpha-fetoprotein-producing serous carcinoma of the uterus metastasizing to the ovaries, mimicking primary ovarian yolk sac tumor: a case report and review of the literature
Q38297206Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma
Q40115732Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients.
Q36341198Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival
Q34899256Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma
Q38625315An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
Q80337829An unusual composite endometrial tumor combining papillary serous carcinoma and small cell carcinoma
Q43284687An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Q61898793Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study
Q64262530Anaphylaxis Induced by Sugammadex in a Patient with Papillary Serous Carcinoma of the Uterine Adnexa Undergoing Exploratory Laparotomy
Q94591600Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?
Q90672793Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
Q88640647Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)
Q50964902Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum.
Q92950797Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma
Q35840413Association between uterine serous carcinoma and breast cancer
Q85327489Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Q52431522Author Correction: CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Q91709261Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models
Q33992783Axillary metastasis from an occult tubal serous carcinoma in a patient with ipsilateral breast carcinoma: a potential diagnostic pitfall
Q40523803B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
Q59125630BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
Q91994058BRAFV600E -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
Q77385661BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum
Q38403255BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines
Q73574334BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis
Q33832014Bilateral Primary Papillary Serous Carcinoma of the Fallopian Tube
Q51781362Bilateral micropapillary serous carcinoma of the ovary: a case report.
Q36801308Bilateral primary fallopian tube papillary serous carcinoma in postmenopausal woman: Report of two cases
Q51107512Bilateral synchronous high-grade serous carcinoma and clear cell carcinoma in right and left ovaries with immunohistochemical confirmation: an exceptional finding.
Q84218716Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites
Q92845245Bleeding and bowel obstruction in giant ovarian serous carcinoma - a video vignette
Q35614139Brain metastasis from uterine serous carcinoma: A case report and review of literature
Q36039847Brain metastasis in two patients with stage IA papillary serous carcinoma of the uterus
Q90964269Breast metastases: A rare manifestation of advanced uterine serous carcinoma
Q74519472CA 125 may not reflect disease status in patients with uterine serous carcinoma
Q69684182CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma
Q42365333CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
Q51536234CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
Q76892093CONSIDERATIONS AND ANATOMO-CLINICAL OBSERVATIONS ON SEROUS CARCINOMA OF THE OVARY
Q47141255CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity
Q77186620CT appearance of primary papillary serous carcinoma of the peritoneum
Q38367063CT features of low grade serous carcinoma of the ovary
Q44261967Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Q64091838Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?
Q89350027Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma
Q26998068Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma
Q47588829Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Q102214462Carcinosarcoma of the ovary: MR and clinical findings compared with high-grade serous carcinoma
Q92025518Case of a Sister Mary Joseph's Nodule in a High Grade Serous Carcinoma
Q87414046Case of uterine papillary serous carcinoma following tamoxifen treatment that could not be diagnosed during screening
Q91590494Cathepsin L-induced galectin-1 may act as a proangiogenic factor in the metastasis of high-grade serous carcinoma
Q84016865Cervical metastasis as the first manifestation of ovarian papillary serous carcinoma
Q92293438Characteristics and prognostic significance of incidentally detected cancer cells in uterine specimens of patients with pelvic high-grade serous carcinoma
Q57297686Characterization of Risk Factors and Timing of Venous Thromboembolism in Patients With Uterine Serous Carcinoma
Q98499784Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma
Q92714424Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma
Q35519808Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma
Q68384787Chemotherapeutic approach to uterine papillary serous carcinoma
Q89902069Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy
Q42938103Choriocarcinoma arising in a serous carcinoma of ovary: an example of histopathology driving treatment
Q81571883Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma
Q79918669Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma
Q39167159Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
Q83422587Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial
Q77719756Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma
Q89529848Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
Q33912347Clinical Relevance of Increased Endothelial and Mesothelial Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with Metastatic Ovarian High-Grade Serous Carcinoma
Q30278404Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp
Q64115689Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers
Q44043688Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study
Q45353174Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen
Q35575176Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.
Q81257215Clinical significance of Her-2/neu overexpression in uterine serous carcinoma
Q81797649Clinico-cytological study of uterine papillary serous carcinoma
Q44231450Clinico-pathological study of uterine papillary serous carcinoma
Q92168383Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma
Q42774141Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy
Q92248873Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma
Q59135515Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases
Q35007178Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma
Q95938188Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma
Q84380481Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival
Q37122620Coexistence of tuberculous peritonitis and primary papillary serous carcinoma of the peritoneum: a case report and review of the literature
Q84082908Coexisting serous carcinoma of the endometrium and the fallopian tube
Q91136543Colon Metastasis From Microscopic Serous Carcinoma of the Fallopian Tube Fimbria Mimicking a Primary Colon Cancer
Q84782227Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology
Q88274237Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma
Q55452489Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer.
Q94549095Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma
Q50457157Combined hepatoid and serous carcinoma of the uterine corpus: an undescribed phenomenon
Q79767213Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread
Q86588909Combined serous carcinoma and neuroendocrine carcinoma of the fallopian tube
Q38856165Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital
Q33751321Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight
Q99233074Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma
Q35694661Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients
Q36231169Comparison of Survival Benefits of Combined Chemotherapy and Radiotherapy Versus Chemotherapy Alone for Uterine Serous Carcinoma: A Meta-analysis
Q67947147Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma
Q38179804Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary
Q87486235Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma
Q57477819Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma
Q92361587Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination
Q79825860Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
Q74645088Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma
Q41671863Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin
Q46846828Complete response to docetaxel and carboplatin combination chemotherapy for a stage IV uterine papillary serous carcinoma: a case report
Q98514607Comprehensive pelvic and paraaortic lymphadenectomy in patients with apparently early stage uterine serous carcinoma - an anachronism?
Q71351423Computed tomography of uterine papillary serous carcinoma
Q92433614Concurrent high-grade serous carcinoma and borderline tumor demonstrating different chemo-sensitivity
Q72632226Concurrent ovarian serous carcinoma and osteogenesis imperfecta
Q35580726Concurrent primary peritoneal low-grade serous carcinoma and endometrial high-grade serous carcinoma
Q123915515Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
Q89178904Continuous successful re-aspirating a large obstructive pelvic cystic mass of low grade serous carcinoma after failed sclerotherapy
Q92131983Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma
Q38058666Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study
Q89843390Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448]
Q37232123Critical molecular abnormalities in high-grade serous carcinoma of the ovary
Q88908047Culprit or Bystander? The Role of the Fallopian Tube in "Ovarian" High-Grade Serous Carcinoma
Q53335378Cutaneous metastasis of uterine papillary serous carcinoma presenting as a solitary nodule on the umbilical area.
Q69945905Cytologic features of endometrial papillary serous carcinoma
Q74650130Cytologic features of villoglandular adenocarcinoma of the uterine cervix: comparison with typical endocervical adenocarcinoma with a villoglandular component and papillary serous carcinoma
Q64083374Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma
Q59809954Cytology of the fallopian tube: A screening model for high-grade serous carcinoma
Q99239481Cytology positive pericardial effusion causing tamponade in patients with high grade serous carcinoma of the ovary
Q50919255Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Q96349349Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Q72253228Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma
Q34595670Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma
Q46314878Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Q93168394Defining the molecular evolution of extrauterine high grade serous carcinoma
Q64375199Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling
Q80550856Depressed host immunity in a case of metachronous primary uterine papillary serous carcinoma and non-Hodgkin's lymphoma
Q77228471Dermatomyositis and peritoneal papillary serous carcinoma
Q100737232Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays
Q34634149Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
Q88373802Diagnosis of primary peritoneal high-grade serous carcinoma in a man by cytology
Q53286591Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion.
Q96228507Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma
Q80352442Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps
Q92524991Differential expression of immune related genes in high-grade ovarian serous carcinoma
Q33233449Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma
Q47749903Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage
Q73965128Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum
Q41557623Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
Q30446831Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin
Q38283056Distribution and volume of extrauterine disease in uterine serous carcinoma: is minimally invasive surgery a suitable approach?
Q35927368Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
Q34103978Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Q34714574Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts
Q36258125Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Q34222070EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells?
Q38971615ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy
Q88434848Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?
Q46069036Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery
Q45268051Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.
Q53327771Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.
Q38074214Early stage uterine serous carcinoma: management updates and genomic advances
Q74159586Early uterine serous carcinoma: clonal origin of extrauterine disease
Q53356684Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
Q72636529Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent
Q88990761Efficacy of endocervical curettage and CA-125 measurement in endometrial serous carcinoma: A case series and literature review
Q84155693Endobronchial metastasis from primary papillary serous carcinoma of the peritoneum
Q34978084Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Q26695612Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma
Q43848072Endometrial Serous Carcinoma With Clear-Cell Change: Frequency and Immunohistochemical Analysis
Q41019634Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression
Q41156485Endometrial papillary serous carcinoma: patterns of spread and treatment
Q36003197Endometrial serous carcinoma (uterine papillary serous carcinoma): precancerous lesions and the theoretical promise of a preventive approach.
Q37017041Endometrial serous carcinoma: its molecular characteristics and histology-specific treatment strategies
Q39035328Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up
Q44498721Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers
Q39208636Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients
Q91707855Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma
Q51746639Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
Q88347253Erratum: Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion
Q39955890Establishment and characterization of a human cell line derived from a uterine papillary serous carcinoma with wild-type p53 function
Q68969086Evaluation of PAS-diastase and carcinoembryonic antigen staining in the differential diagnosis of malignant mesothelioma and papillary serous carcinoma of the ovary
Q74099950Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma
Q80262379Evaluation of normal-sized ovaries associated with primary peritoneal serous carcinoma for possible precursors of ovarian serous carcinoma
Q34457825Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Q72454022Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum
Q40515254Evolutive peritoneal disease after conservative management and the use of infertility drugs in a patient with stage IIIC borderline micro-papillary serous carcinoma (MPSC) of the ovary: case report
Q77593219Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum
Q47762675Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma
Q41219933Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival
Q48792129Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
Q92408734Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma
Q44544392Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium
Q81475966Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival
Q44053802Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival.
Q86945717Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma
Q37388641Expression of p-Akt in ovarian serous carcinoma and its association with proliferation and apoptosis
Q98188493Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma
Q96023330Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
Q39675522Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary
Q88875414Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
Q73824541Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease
Q37229341Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival
Q48649110External pelvic and vaginal irradiation vs. vaginal irradiation alone as postoperative therapy in women with early stage uterine serous carcinoma: Results of a National Cancer Database analysis.
Q38964462Extrauterine Spread, Adjuvant Treatment, and Prognosis in Noninvasive Uterine Papillary Serous Carcinoma of the Endometrium: A Retrospective Multicenter Study.
Q46138913FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival
Q39203802FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome
Q94683666Fallopian tube abnormalities in uterine serous carcinoma
Q88024397Fallopian tube high-grade serous carcinoma with intramucosal spread and presenting as a malignancy on pap smear
Q44432679False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation
Q77310541Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case
Q36040635Fatal cardiac tamponade following cytoreductive surgery for serous carcinoma of the ovary
Q53758785Fine needle aspiration cytology of a nodal low-grade serous neoplasm: a case report of low-grade serous carcinoma arising from a serous borderline tumour with cyto-histological correlation.
Q40212189Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study
Q57176040GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells
Q91262242Gastrointestinal: Successful diagnosis of primary peritoneal serous carcinoma by endoscopic ultrasound-guided through-the-needle forceps biopsy
Q37050667Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages
Q34713009Gene expression profiles in stage I uterine serous carcinoma in comparison to grade 3 and grade 1 stage I endometrioid adenocarcinoma
Q37580229Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
Q38308209Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
Q73469351Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum
Q38471333Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum
Q42446598Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer
Q64080187Global epidemiology, risk factors, and histological types of ovarian cancers in Trinidad
Q44618222Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Q79934949Grading ovarian serous carcinoma using a two-tier system
Q33693203Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
Q52567521Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
Q104129844HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting
Q97561186HER2 Testing in Endometrial Serous Carcinoma
Q39098938HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
Q83811112HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Q83188780HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma
Q84866516HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes
Q45953122HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Q41071376HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Q80396741Her-2/neu overexpression and amplification in uterine papillary serous carcinoma
Q35527141Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
Q83867495High grade serous carcinoma of the ovary with a yolk sac tumour component in a postmenopausal woman: report of an extremely rare phenomenon
Q38720158High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum
Q91871554High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
Q100433330High-Grade Serous Carcinoma of the Fallopian Tube
Q35210293High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
Q91598628High-grade Pelvic Serous Carcinoma Within the Fallopian Tube Lumen: Real or Artifact?
Q51753726High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
Q47150076High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
Q47811275High-grade serous carcinoma arising in a low-grade serous carcinoma and micropapillary serous borderline tumour of the ovary in a 23-year-old woman
Q97532129High-grade serous carcinoma of fallopian tube with yolk sac tumor differentiation in a postmenopausal patient
Q37553367High-grade serous carcinoma of the ovary
Q38687061High-grade serous carcinoma of tubo-ovarian origin: recent developments.
Q55347281High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis.
Q60910235High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature
Q91228892Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results
Q35510378Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum
Q97691132Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
Q91653197Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression
Q37286791Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer
Q53470669IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma.
Q73377447Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum
Q73622085Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum
Q53247084Identification of a preoperative predictive factor for lymph node metastasis in uterine papillary serous carcinoma: long-term results from a single institution.
Q97592738Identification of aberrantly expressed long non-coding RNAs in ovarian high-grade serous carcinoma cells
Q34393919Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
Q96952577Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice
Q85493415Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma
Q100425897Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma
Q96581801IgG4-Related Disease with Ascites: Report of a Case Simulating Primary Peritoneal Papillary Serous Carcinoma
Q95273459Imaging features of primary peritoneal serous carcinoma: A case report
Q46948132Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful
Q95591382Immunohistochemical c-kit expression in uterine serous carcinoma tissue
Q82723168Immunohistochemical characterization of endocervical papillary serous carcinoma
Q87556647Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma
Q80506055Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma
Q43997124Immunophenotyping of serous carcinoma of the female genital tract
Q89421055Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma
Q35947034Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
Q38855844Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus
Q81297998Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma
Q36750622Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum.
Q34432555Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
Q48345561Improving the cytological diagnosis of high-grade serous carcinoma in ascites with a panel of complementary biomarkers in cell blocks
Q89601813Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation
Q88434551Incidental Small Ovarian Surface Serous Carcinoma With Miliary Abdominal Seeding During Robotic-Assisted Total Hysterectomy
Q41678534Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series
Q33986711Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival
Q92332337Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database
Q77789601Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma
Q89239902Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Q39011970Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model
Q37148431Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway
Q94459634Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla-Site of Origin of Serous Carcinoma of the Ovary
Q33761023Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria
Q52881563Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway.
Q53337533Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
Q53009456Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
Q81420853Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study
Q51786033Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: the Indiana University experience.
Q93335726Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis
Q90255806Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study
Q72253272Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)
Q37146082Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes
Q35104225Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency
Q91990276In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma
Q40170913Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Q74715857Is micropapillary serous carcinoma for real?
Q74033619Is papillary serous carcinoma of the peritoneum (PSCP) a multifocal disease?
Q53082153Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
Q48685364Julian CG, Woodruff JD. The biologic behavior of low-grade papillary serous carcinoma of the ovary. Obstet Gynecol 1972; 40:860-7.
Q98902335KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
Q33893010KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma
Q57791800Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis
Q37349904Large cell neuroendocrine carcinoma of the ovary associated with serous carcinoma with mucin production: a case report and literature review.
Q39042556Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
Q35607666Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
Q47218847Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
Q85190056Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma
Q74525507Long-term survival of a patient with primary papillary serous carcinoma of the peritoneum treated by subtotal peritonectomy plus intraoperative chemohyperthermia
Q47320277Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum
Q35132433Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma
Q80456258Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma
Q42365263Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium
Q37452286Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival
Q104136011Loss of tubal ciliated cells as a risk for "ovarian" or pelvic serous carcinoma
Q96230943Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa
Q33527712Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary
Q53278948Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Q50856533Low-grade serous carcinoma of the ovary or peritoneum.
Q38514737Low-grade serous carcinoma: molecular features and contemporary treatment strategies
Q38109432Low-grade serous carcinoma: new concepts and emerging therapies.
Q91288786Lymphatic Invasion in the Fallopian Tube is a Late Event in the Progression of Pelvic Serous Carcinoma and Correlates With Distant Metastasis
Q37316711MAD2 Expression in Ovarian Carcinoma: Different Expression Patterns and Levels among Various Types of Ovarian Carcinoma and Its Prognostic Significance in High-Grade Serous Carcinoma
Q81597613MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium
Q91557739MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor
Q96637714Magnetic resonance imaging findings of extrauterine high-grade serous carcinoma based on new pathologic criteria for primary site assignment
Q50115349Malignant Endometrial Polyps in Uterine Serous Carcinoma: The Prognostic Value of Polyp Size and Lymphovascular Invasion
Q80456304Malignant mixed müllerian tumor of the fallopian tube coincident with a primary serous carcinoma of the ovary. Case report
Q74310041Malignant mullerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases
Q77932350Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium
Q95382817Masquerading as Sigmoid Adenocarcinoma: A Unique Presentation of High-Grade Serous Carcinoma Arising from Endometriosis
Q92643955Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma
Q91851414Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it
Q91648665Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment
Q58789603Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel
Q92321835Metastatic Carcinoma of Endometrium from Primary Ovarian Serous Carcinoma Mimicking a Primary Uterine Tumour
Q62112710Metastatic Ovarian Serous Carcinoma Presenting as Inflammatory Breast Cancer: A Case Report
Q48164105Metastatic Ovarian Serous Carcinoma of the Breast.
Q57094535Metastatic Squamous Cell Carcinoma versus Primary High Grade Serous Carcinoma of the Ovary
Q42796773Metastatic ovarian papillary serous carcinoma to the breast: Diagnosis and pitfalls
Q90465720Metastatic peripancreatic lymph nodes resection during primary debulking surgery for primary peritoneal serous carcinoma
Q37876750Metastatic serous carcinoma of the testis: a case report and review of the literature.
Q48197150Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-Report of two cases and literature review
Q46234989Metastatic uterine papillary serous carcinoma to the pericardium
Q81669706Metastatic uterine serous carcinoma originating in an endometrial polyp: a report of 2 cases
Q28486318Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners
Q98164275MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma
Q92858992MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma
Q42669113Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas
Q45100967Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors
Q73451474Micropapillary serous carcinoma of the ovary: a report of three cases
Q74219935Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53
Q34072369Micropapillary serous carcinoma of the ovary: case report and review of literature
Q74455494Micropapillary serous carcinoma of the ovary: cytomorphologic characteristics in peritoneal/pelvic washings
Q72850970Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma
Q50049913Microsatellite instability-high endocervical serous carcinoma manifesting as pulmonary thromboembolism: A case report and review of the literature.
Q36553567Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Q84972872Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: an immunohistochemical study of 13 cases
Q80608581Minimal uterine serous carcinoma: a clinicopathological study of 40 cases
Q36762035Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis
Q33937418Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation
Q61840587Mixed endometrioid and serous carcinoma developing in abdominal wall endometriosis following Cesarean section
Q92120418Mixed large and small cell neuroendocrine carcinoma of the endometrium with serous carcinoma: A case report and literature review
Q81227523Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases
Q80421554Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin
Q37119791Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms
Q36416465Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
Q104562625Molecular analysis of a rare case of low-grade primary peritoneal serous carcinoma in a male
Q34682062Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum
Q47979918Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations
Q37197308Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium
Q30430198Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma
Q91758702Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology
Q48541433Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma.
Q36037099Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Q69879973Multiple focal extraovarian serous carcinoma
Q69782356Multiple focal extraovarian serous carcinoma; three case reports
Q83698217Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma
Q90317700Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions
Q34729698Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Q71215858Neoadjuvant chemotherapy in uterine papillary serous carcinoma
Q38965974Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
Q34543315New views on the pathogenesis of high-grade pelvic serous carcinoma with suggestions for advancing future research
Q77420326No BRCA1 germline mutation in a family with uterine papillary serous carcinoma: a case report
Q68016672Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels
Q46517040Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia
Q47888032Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases
Q95719057Noninvasive papillary serous carcinoma of the endometrium
Q50658626Normal-sized ovarian papillary serous carcinoma: a case report
Q53093440Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Q57171344ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro
Q87752008Occult serous carcinoma of fallopian tube presenting as supraclavicular lymphadenopathy
Q79467462Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma
Q39119683Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
Q34473693Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.
Q46673327Optimal surgical debulking in uterine papillary serous carcinoma affects survival
Q26852698Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Q34728110Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Q40554058Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy
Q38300943Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy
Q79931185Outcomes in surgical stage I uterine papillary serous carcinoma
Q58763140Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience
Q64053341Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
Q39660398Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system
Q92086542Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes
Q47144220Ovarian Large Cell Neuroendocrine Carcinoma Associated with Serous Carcinoma: Correlation of Pathology with MR Imaging
Q104479678Ovarian Seromucinous Carcinoma With Extensive Bilateral Fallopian Tubes Metastases by the Low-grade Serous Carcinoma Component Mimicking Serous Tubal Intraepithelial Carcinoma: Case Presentation and Literature Review
Q87108036Ovarian Yolk Sac Tumor With High-Grade Serous Carcinoma in a 62-Year-Old Woman
Q35732549Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor
Q38007297Ovarian low-grade serous carcinoma: a comprehensive update
Q40762738Ovarian lymphoma and serous carcinoma of low malignant potential arising in the same ovary. A case report with literature review of 14 primary ovarian lymphomas.
Q46008296Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern.
Q92867921Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature
Q57764870Ovarian serous carcinoma presenting with mediastinal lymphadenopathy 20 months before the intraabdominal mass: Role of immunohistochemistry
Q85055443Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression
Q44548482Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum
Q73544510Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma
Q71203864Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease
Q94564706PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-Ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
Q40389999PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors
Q43539364PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma
Q30434644PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma
Q89345179Papillary Serous Carcinoma of the Peritoneum Mimicking an Ovarian Cyst in Pregnancy
Q79969294Papillary serous carcinoma arising from adenomyosis presenting as intramural leiomyoma
Q82539042Papillary serous carcinoma arising in abdominal wall endometriosis treated with neoadjuvant chemotherapy and surgery
Q36769540Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma
Q84104948Papillary serous carcinoma in situ in ovarian endometriosis in an MSH2 mutation carrier
Q81670753Papillary serous carcinoma of ovarian type of the testis with borderline differentiation
Q34468842Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Q53514541Papillary serous carcinoma of peritoneum: presentation of 2 cases.
Q81327989Papillary serous carcinoma of the broad ligament: a rare case report
Q41813547Papillary serous carcinoma of the cervix mixed with squamous cells: A report of the first case
Q77362148Papillary serous carcinoma of the cervix: ultrasonographic findings
Q33690133Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment
Q68690263Papillary serous carcinoma of the ovary with squamous differentiation
Q80836150Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study
Q72693859Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma
Q41086283Papillary serous carcinoma of the peritoneum
Q44099816Papillary serous carcinoma of the peritoneum
Q38458052Papillary serous carcinoma of the peritoneum coexisting with or after endometrial carcinoma
Q68018399Papillary serous carcinoma of the peritoneum following endometrial cancer
Q50905113Papillary serous carcinoma of the peritoneum in a man: a case report.
Q71067204Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study
Q79739656Papillary serous carcinoma of the peritoneum with paraaortic lymph node metastasis despite minimal intraperitoneal involvement: a case report
Q38134731Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy
Q74033590Papillary serous carcinoma of the peritoneum: analysis of clonality of peritoneal tumors
Q72694363Papillary serous carcinoma of the retroperitoneum
Q73458096Papillary serous carcinoma of the tunica vaginalis testis
Q37673727Papillary serous carcinoma of the uterine cervix with lung metastasis
Q74015315Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases
Q71224613Papillary serous carcinoma of the uterus arising in an adenomyoma
Q77323324Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma
Q68944031Papillary serous carcinoma with basophilic cytoplasmic granules
Q83878105Papillary syncytial metaplasia associated with endometrial breakdown exhibits an immunophenotype that overlaps with uterine serous carcinoma
Q72053828Paraneoplastic Hypercalcemia Associated with Uterine Papillary Serous Carcinoma
Q33561544Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin
Q90399148Pathogenesis and Clinical Management of Uterine Serous Carcinoma
Q34402523Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma
Q81222569Pathologic quiz case: a 54-year-old woman with bilateral pelvic masses. Well-differentiated papillary serous carcinoma arising in serous adenofibroma of borderline malignancy
Q92225127Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
Q88395436Patient with Proteus syndrome and paratesticular ovarian-type papillary serous carcinoma
Q85112344Patterns of Low-grade Serous Carcinoma With Emphasis on the Nonepithelial-lined Spaces Pattern of Invasion and the Disorganized Orphan Papillae
Q41435144Patterns of care, associations and outcomes of chemotherapy for uterine serous carcinoma: analysis of the National Cancer Database
Q46263824Patterns of relapse in stage I-II uterine papillary serous carcinoma treated with adjuvant intravaginal radiation (IVRT) with or without chemotherapy
Q58088279Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma
Q34829897Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin
Q80488783Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report
Q51559692Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Q72130957Peritoneal papillary serous carcinoma arising in an infertile woman during ovulation-induction therapy: immunohistochemical expression of LH/hCG receptors
Q70496431Peritoneal papillary serous carcinoma in a woman with a history of utero DES exposure
Q69587609Peritoneal papillary serous carcinoma with long-term survival
Q72034942Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease
Q64969180Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma.
Q53174208Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger.
Q92952211Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma
Q86194171Photodynamic detection and management of intraperitoneal spreading of primary peritoneal papillary serous carcinoma in a man: report of a case
Q33377350Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Q50481932Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Q86145706Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients
Q96950416Poorer prognosis of ovarian squamous cell carcinoma than serous carcinoma: a propensity score matching analysis based on the SEER database
Q86708409Population-based treatment and outcomes of Stage I uterine serous carcinoma
Q44165705Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC).
Q28072095Practical issues in the diagnosis of serous carcinoma of the endometrium
Q86046480Precursor lesions and prognostic factors in primary peritoneal serous carcinoma
Q37399709Precursors to pelvic serous carcinoma and their clinical implications
Q34552129Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma
Q84734401Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients
Q94518598Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology
Q91634050Primary Peritoneal Low-grade Serous Carcinoma in a Patient With Lynch Syndrome: A Case Report
Q93245955Primary Peritoneal Serous Carcinoma Detected by Abnormal Cervical Smear: a Case Report
Q40182860Primary Peritoneal Serous Carcinoma in Men: A Rare and Non-BRCA-associated Entity
Q85588429Primary high-grade serous carcinoma arising in the urethra or urethral diverticulum: a report of 2 cases of an extremely rare phenomenon
Q98906043Primary mixed large cell neuroendocrine and high grade serous carcinoma of the endometrium
Q37231008Primary papillary serous carcinoma of the peritoneum diagnosed by video-assisted thoracoscopic surgery: report of a case
Q73998284Primary papillary serous carcinoma of the peritoneum in a man
Q73917710Primary papillary serous carcinoma of the peritoneum: CT-pathologic correlation
Q67925647Primary papillary serous carcinoma of the peritoneum: a case of complete remission of bulky peritoneal disease after chemotherapy
Q35877546Primary papillary serous carcinoma of the peritoneum: four cases and review of computed tomography findings
Q36787135Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry
Q45773745Primary peritoneal low-grade serous carcinoma forming a mass in the colon mimicking a colonic primary carcinoma: a case report
Q83488841Primary peritoneal serous carcinoma presenting as inflammatory breast cancer
Q44556615Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.
Q37379544Primary peritoneal serous carcinoma with signet ring cells
Q36954614Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
Q36305409Primary peritoneal serous carcinoma: a clinicopathological and immunohistochemical study of six cases
Q34032865Primary peritoneal serous carcinoma: a rare case and palliative approach
Q71447480Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma
Q37052072Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report
Q68044750Primary serous carcinoma of the female peritoneum. Report of a case with a re-examination of a histogenetic problem based on the use of a specific antimesothelial-cell antibody
Q80387943Primary serous carcinoma of the peritoneum producing granulocyte colony-stimulating factor
Q50236868Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide
Q67555431Primary, papillary serous carcinoma of the peritoneum; a report of experiences
Q36592537Profile of differentially expressed miRNAs in high-grade serous carcinoma and clear cell ovarian carcinoma, and the expression of miR-510 in ovarian carcinoma
Q34345071Prognosis for papillary serous carcinoma of the endometrium after surgical staging
Q37975098Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review
Q84689911Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma
Q80230332Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma
Q55261133Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.
Q93057055Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic high-grade serous carcinoma
Q27853285Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
Q80550802Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma
Q81333205Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary
Q58595581Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the coeur cohort
Q38306666Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions
Q81535180Proliferating multicentric reticulohistiocytosis associated with papillary serous carcinoma of the endometrium
Q94491524Proteomic Analysis of Transitional Cell Carcinoma-Like Variant of Tubo-Ovarian High-Grade Serous Carcinoma
Q86746941Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Q68619006Psammoma bodies in serous carcinoma of the ovary. A prognostic study
Q44052187Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Q40524250Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011.
Q52605005Radiation-associated Angiosarcoma Mimicking Fallopian Tube High-grade Serous Carcinoma in a Woman With De Novo Li-Fraumeni Syndrome.
Q78056451Rapid death following papillary serous carcinoma of the endometrium without myometrial invasion
Q37295240Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: fact or artifact?
Q53419279Rare case of coexistence of primary ovarian carcinoid in mature teratoma with primary serous carcinoma in second ovary--a case report.
Q92992169Rare case of paraneoplastic cerebellar degeneration secondary to high-grade serous carcinoma of tubo-ovarian origin
Q40729497Rare form of extraovarian primary peritoneal papillary serous carcinoma with solitary cystic lesion mimicking a liver tumor; report of a case
Q30250107Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence
Q72297401Re: Uterine papillary serous carcinoma: patterns of metastatic spread
Q84869461Reactive tubal epithelium mimicking Mullerian serous carcinoma: pitfalls in the evaluation of pelvic wash specimens
Q34201837Recent advances in the understanding of the pathogenesis of serous carcinoma: the concept of low- and high-grade disease and the role of the fallopian tube.
Q74715917Recurrent micropapillary serous ovarian carcinoma
Q42594882Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine
Q92003108Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
Q92443807Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre
Q37524030Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).
Q73133753Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report
Q82446554Retroperitoneal tuberculosis in a patient with uterine papillary serous carcinoma
Q37502654Rhabdomyosarcoma arising in a mature cystic teratoma with contralateral serous carcinoma: case report and review of the literature
Q39886748Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
Q91798983Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma
Q98509041S100A4/non-muscle myosin IIA/p53 axis contributes to aggressive features in ovarian high-grade serous carcinoma
Q92572537SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
Q50020012STAT3/PIAS3 levels serve as "early signature" genes in the development of high-grade serous carcinoma from the fallopian tube
Q38766901SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Q55456064Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.
Q89879980Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding
Q90094958Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
Q36768921Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
Q91327127Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma
Q45980545Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Q48515431Serous Carcinoma of the Uterine Cervix, an Extremely Rare Aggressive Entity: A Literature Review.
Q81420801Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management
Q47737327Serous carcinoma arising from adenomyosis
Q36969096Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases
Q73155676Serous carcinoma arising in an adenofibroma of the endometrium
Q43421930Serous carcinoma arising in endometrial polyps: clinicopathologic study of 4 cases
Q44773054Serous carcinoma in endometrial polyps
Q98946974Serous carcinoma of a prolapsed fallopian tube: A rare cause of a vaginal apex mass
Q37146313Serous carcinoma of endometrium in combination with neuroendocrine small-cell: A case report and literature review
Q36523858Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types
Q82739434Serous carcinoma of the fallopian tube presenting as axillary lymphadenopathy
Q81092327Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall
Q38125072Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review
Q80464993Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy
Q70007943Serous carcinoma of the ovary: CT identification of metastatic calcified implants
Q68583258Serous carcinoma of the ovary: value of computed tomography in detection of calcified pleural and pulmonary metastatic implants
Q45733721Serous carcinoma of the peritoneum after oophorectomy
Q39349153Serous carcinoma of the testicle and paratesticular tissue: Case Report and Literature Review
Q90896657Serous carcinoma of the uterine cervix: Clinicopathological features differing from serous carcinomas of other female organs
Q46773197Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation
Q30461903Serous surface papillary carcinoma. A clinicopathologic study of 10 cases and comparison with stage III-IV ovarian serous carcinoma
Q41445288Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
Q53140410Serous tubal intraepithelial carcinoma, chronic fallopian tube injury, and serous carcinoma development.
Q37125079Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention
Q73258220Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma
Q91608882Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma
Q46380307Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.
Q53677145Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?
Q46988991Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis
Q80163837Skin metastases revealing a bilateral ovarian invasive micropapillary serous carcinoma
Q60914787Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube
Q31123493Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma
Q54054684Sonographic depiction of non-palpable uterine papillary serous carcinoma metastasis embedded within the abdominal wall.
Q51138602Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion.
Q37965359Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival
Q73981687Stage IA uterine serous carcinoma: a study of 13 cases
Q83135150Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Q91718293Stage III uterine serous carcinoma: modern trends in multimodality treatment
Q53092471Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses.
Q33743091Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
Q98204669Stemness in high-grade serous carcinoma of tubo-ovarian origin causes multiple immunohistochemical pitfalls: a case report
Q64083343Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma
Q33366370Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data
Q91025908Successful multidisciplinary treatment of uterine serous carcinoma in a patient who had previously undergone renal transplantation
Q92433890Successful radiotherapy for endometrial serous carcinoma with local repeated recurrence
Q96642204Superior vena cava syndrome associated with uterine serous carcinoma
Q89868575Surprise Lymph Node Histology in a Patient with Ovarian Serous Carcinoma
Q48922677Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study
Q98514592Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma
Q38967788Synchronous Low-grade Appendiceal Mucinous Neoplasm and Primary Peritoneal Low-grade Serous Carcinoma: A First Description of These 2 Neoplasms Presenting Together as Suspected Peritoneal Carcinomatosis.
Q51214003Synchronous carcinosarcoma uterus and primary serous carcinoma of bilateral fallopian tubes: a case report.
Q34491116Synchronous occurrence of endometrial stromal nodule with papillary serous carcinoma of ovary: report of a case and brief review of literature
Q46451745Synchronous ovarian granulosa cell tumor and uterine serous carcinoma: a rare association of a high-risk endometrial cancer with anestrogenic ovarian tumor
Q61808108Synchronous renal and para-aortic metastasis in a uterine serous carcinoma: A case review and clinical considerations
Q71544451Syndrome of inappropriate antidiuresis in ovarian serous carcinoma with neuroendocrine differentiation
Q39123683Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
Q93126756Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing
Q34998509T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
Q47350535TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.
Q93021925Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern
Q37699264Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer
Q60924976Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
Q64094681Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation
Q51609396Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
Q34729807Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
Q100993037Testicular papillary serous carcinoma of ovarian type, a rare case report, however an important timely diagnostic issue
Q79862089Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum
Q90301593The "Far Left" of the Morphologic Spectrum of Ovarian High-Grade Serous Carcinoma: Case Report of a Purely Noninvasive High-Grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor
Q40253367The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary
Q40500136The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians
Q69387829The biologic behavior of low-grade papillary serous carcinoma of the ovary
Q36624703The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
Q34179788The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression
Q89074328The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Q41747755The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Q46595130The cytomorphology of papillary serous carcinoma of the endometrium in cervical smears
Q36994615The development of papillary serous carcinoma of the peritoneum subsequent to endometrial carcinoma: a case report and review of the literature
Q79772649The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma
Q79080812The effect of cyclooxygenase‐2 expression on tumor vascularity in advanced stage ovarian serous carcinoma
Q48774780The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
Q84635438The evolving pathogenesis model of high-grade pelvic serous carcinoma
Q82941868The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma
Q90021710The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma
Q73459314The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways
Q100497506The immune complex p53 protein/anti-p53 autoantibodies in the pathogenesis of ovarian serous carcinoma
Q81872426The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma
Q36475131The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone.
Q37850052The impact of race on survival in uterine serous carcinoma: a hospital-based study
Q58073798The importance of chemotherapy and radiation in uterine papillary serous carcinoma
Q86702474The importance of surgical staging in women with uterine serous carcinoma: experience in a single institution reveals a survival benefit
Q38110044The life and times of low-grade serous carcinoma of the ovary
Q98574953The methylomic landscape of fallopian tube lesions associated with ovarian high-grade serous carcinoma
Q80556503The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma
Q100473017The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Q44239150The prognosis in early endometrial carcinoma. The importance of uterine papillary serous carcinoma (UPSC), age, FIGO grade and nuclear grade
Q38427509The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary
Q47111746The prognostic value of Ki67 in ovarian high-grade serous carcinoma: an 11-year cohort study of Chinese patients
Q73691527The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma
Q97691128The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance
Q90090414The role of omentectomy in the surgical treatment of uterine serous carcinoma
Q35840405The role of optimal debulking in advanced stage serous carcinoma of the uterus
Q38540739The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters
Q73591470The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing?
Q78038994The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma
Q69722257Therapeutic approaches to uterine papillary serous carcinoma: a preliminary report
Q53539806Three-dimensional power doppler ultrasound is useful to monitor the response to treatment in a patient with primary papillary serous carcinoma of the peritoneum.
Q95499783Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site
Q44522454Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Q38047180Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor.
Q104739133Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis
Q51814615Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Q34293815Treatment of uterine papillary serous carcinoma with paclitaxel
Q36412970Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel
Q40179085Trends in Survival of Patients With Uterine Serous Carcinoma From 1988 to 2011: A Population-Based Study
Q71856659Tubal (serous) carcinoma of the endometrium
Q64063717Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study
Q84436616Tubal origin of 'ovarian' low-grade serous carcinoma
Q36169161Tuberous sclerosis complex associated with papillary serous carcinoma of the peritoneum, lymphangioleiomyomatosis, and angiomyolipoma
Q90611516Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles
Q102375662Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements
Q91541829Tumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma
Q91474691Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma
Q81377645Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
Q84483062Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma
Q71355889Ultrastructure of papillary serous carcinoma of the endometrium
Q88138370Undiagnosed tubal high-grade serous carcinoma metastatic to synchronous benign ovarian Brenner tumor
Q90156646Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC
Q93022363Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients
Q38640219Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases
Q54262262Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)
Q70789016Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases
Q35607764Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
Q74739391Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study
Q35042959Uterine papillary serous carcinoma after pelvic radiation therapy for cancer of the cervix
Q36729547Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix
Q53449426Uterine papillary serous carcinoma evolves via a p53-driven pathway.
Q73591125Uterine papillary serous carcinoma following radiation therapy for carcinoma of cervix: a case report
Q72361873Uterine papillary serous carcinoma in a 32-year-old with Turner's syndrome
Q85948087Uterine papillary serous carcinoma metastatic to the choroid
Q40668211Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Q34192554Uterine papillary serous carcinoma presenting as distant lymph node metastasis
Q72195285Uterine papillary serous carcinoma revisited
Q40671362Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide
Q43989674Uterine papillary serous carcinoma with high levels of serum carcinoembryonic antigen. Response to combination chemotherapy
Q40342686Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma
Q83857347Uterine papillary serous carcinoma: a new paradigm for treatment?
Q36787306Uterine papillary serous carcinoma: a review
Q68203357Uterine papillary serous carcinoma: a review
Q67975840Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma
Q34283694Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy
Q37642512Uterine papillary serous carcinoma: epidemiology, pathogenesis and management
Q74507000Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients
Q36412974Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.
Q37582977Uterine papillary serous carcinoma: patterns of failure and survival.
Q72195288Uterine papillary serous carcinoma: patterns of metastatic spread
Q37301327Uterine papillary serous carcinoma: state of the state
Q74714458Uterine papillary serous carcinoma: study of 19 cases
Q81088714Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Q44619903Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy
Q101451083Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies
Q88087857Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy
Q80268165Uterine serous carcinoma: a comparison of therapy for advanced-stage disease
Q47311133Uterine serous carcinoma: a historic evaluation of therapy
Q30422098Uterine serous carcinoma: increased familial risk for lynch-associated malignancies
Q37724181Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary
Q39997968Utility of folate receptor alpha immunohistochemistry in cytology specimens of metastatic breast carcinoma, metastatic serous carcinoma of Müllerian origin, and primary lung adenocarcinoma.
Q81679477Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma
Q50663650VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.
Q36388827Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update
Q81223439Virchow's node as a first manifestation of ovarian serous carcinoma: case report
Q79836060WT-1 and serous carcinoma
Q62897746WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma
Q81614735WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis
Q84690197WT1, p53 and hormone receptor expression in uterine serous carcinoma
Q36685324YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
Q92885208Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component
Q79842323[Clinical and pathologic analysis of 33 cases of uterine papillary serous carcinoma]
Q83415067[Clinical significance of two-tier grading system of ovarian serous carcinoma]
Q90257392[Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma]
Q81831674[Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma]
Q54458348[Conceptual issues and diagnostic updates on endometrial serous carcinoma and its precursor].
Q104564820[Diagnosis, treatment and prognosis of uterine serous carcinoma]
Q82986986[Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma]
Q83249807[Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma]
Q84037597[II. Endometrial neoplasms 1. Papillary serous carcinoma]
Q95520094[Pathologic features of fallopian tubal fimbriae in patients with endometrial serous carcinoma]
Q83142551[Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case]
Q73065962[Peritoneal papillary serous carcinoma: clinical report]
Q85621791[Peritoneal tumor pathology: case no. 7: poor-differentiated primary peritoneal high-grade serous carcinoma]
Q89941501[Serous Carcinoma of the Peritoneum with Metastases to the Breast and Axillary Lymph Nodes]
Q71400529[Uterine papillary serous carcinoma and papillary endometrial carcinoma: analysis of clinical biological behaviors of 56 cases]
Q82292474[Uterine papillary serous carcinoma: report of a case]
Q84512866[Uterine papillary serous carcinoma]
Q91039509[Uterine serous carcinoma accompany with serous endometrial intraepithelial carcinoma and papillary proliferation of the endometrium: report of a case]
Q73153525beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma
Q39145559miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1.
Q73834155p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma
Q82236202p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy
Q81119402p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium
Q35765367p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
Q73598499ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum
Q98386393xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma

The articles in Wikimedia projects and languages

      Serous carcinomawikipedia

Search more.